Skip to main content
. Author manuscript; available in PMC: 2019 Oct 7.
Published in final edited form as: Breast Cancer Res Treat. 2018 Jun 25;171(3):637–648. doi: 10.1007/s10549-018-4852-5

Fig. 2.

Fig. 2

Clinical outcomes and survival. a Most prevalent toxicities (All grades) in response to everolimus, vinorelbine, trastuzumab therapy. Grade 1 and 2 toxicities are presented in blue; Grade 3–5 toxicities are presented in red. b Waterfall plot of intracranial objective response rates by modified RECIST criteria. c Median time toprogression (TTP) and d median overall survival (OS) in response to everolimus, vinorelbine, trastuzumab among patients with progressive or new brain metastases arising from HER2 positive breast cancer